Literature DB >> 27600363

Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task.

Liam J Nestor1,2, Anna Murphy3, John McGonigle1, Csaba Orban1, Laurence Reed1, Eleanor Taylor3, Remy Flechais1, Louise M Paterson1, Dana Smith2,4, Edward T Bullmore2, Karen D Ersche2,4, John Suckling2, Roger Tait2, Rebecca Elliott3, Bill Deakin3, Ilan Rabiner5, Anne Lingford-Hughes1, David J Nutt1, Barbara Sahakian2,4, Trevor W Robbins2,4.   

Abstract

There is a concerted research effort to investigate brain mechanisms underlying addiction processes that may predicate the development of new compounds for treating addiction. One target is the brain's opioid system, because of its role in the reinforcing effects of substances of abuse. Substance-dependent populations have increased numbers of the mu opioid receptor (MOR) in fronto-striatal regions that predict drug relapse, and demonstrate disturbances in these regions during the processing of non-drug rewards. Naltrexone is currently licensed for alcohol and opiate dependence, and may remediate such disturbances through the blockade of MORs in fronto-striatal reward circuitry. Therefore, we examined the potential acute modulating effects of naltrexone on the anticipation of, and instrumental responding for, non-drug rewards in long-term abstinent alcoholics, alcoholic poly substance-dependent individuals and controls using a monetary incentive delay (MID) task during a randomized double blind placebo controlled functional MRI study. We report that the alcoholic poly substance-dependent group exhibited slower and less accurate instrumental responding compared to alcoholics and controls that was less evident after acute naltrexone treatment. However, naltrexone treatment was unable to remediate disturbances within fronto-striatal regions during reward anticipation and 'missed' rewards in either substance-dependent group. While we have not been able to identify the underlying neural mechanisms for improvement observed with naltrexone in the alcoholic poly-substance dependent group, we can confirm that both substance-dependent groups exhibit substantial neural deficits during an MID task, despite being in long-term abstinence.
© 2016 Society for the Study of Addiction.

Entities:  

Keywords:  Abstinence; naltrexone; reward

Mesh:

Substances:

Year:  2016        PMID: 27600363     DOI: 10.1111/adb.12444

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  12 in total

1.  Acute tramadol enhances brain activity associated with reward anticipation in the nucleus accumbens.

Authors:  Yuki Asari; Yumiko Ikeda; Amane Tateno; Yoshiro Okubo; Takehiko Iijima; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2018-06-27       Impact factor: 4.530

2.  Hazardous or harmful alcohol use and reward processing in people with HIV.

Authors:  Leigh L van den Heuvel; Fatima Ahmed-Leitao; Stefan du Plessis; Graeme Hoddinott; Georgina Spies; Soraya Seedat
Journal:  J Neurovirol       Date:  2022-10-10       Impact factor: 3.739

Review 3.  The Use of Functional Magnetic Resonance Imaging to Test Pharmacotherapies for Alcohol Use Disorder: A Systematic Review.

Authors:  Erica N Grodin; Lara A Ray
Journal:  Alcohol Clin Exp Res       Date:  2019-08-23       Impact factor: 3.455

4.  Response inhibition and fronto-striatal-thalamic circuit dysfunction in cocaine addiction.

Authors:  Wuyi Wang; Patrick D Worhunsky; Sheng Zhang; Thang M Le; Marc N Potenza; Chiang-Shan R Li
Journal:  Drug Alcohol Depend       Date:  2018-09-16       Impact factor: 4.492

5.  Behavioral inhibition and reward processing in college binge drinkers with and without marijuana use.

Authors:  Tien T Tong; Jatin G Vaidya; John R Kramer; Samuel Kuperman; Douglas R Langbehn; Daniel S O'Leary
Journal:  Drug Alcohol Depend       Date:  2020-06-12       Impact factor: 4.492

6.  Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.

Authors:  Aaron C Lim; Dara G Ghahremani; Erica N Grodin; ReJoyce Green; Spencer Bujarski; Emily E Hartwell; Kelly E Courtney; Kent Hutchison; Karen Miotto; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2019-05-09       Impact factor: 4.852

7.  Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.

Authors:  G Savulich; R Riccelli; L Passamonti; M Correia; J F W Deakin; R Elliott; R S A Flechais; A R Lingford-Hughes; J McGonigle; A Murphy; D J Nutt; C Orban; L M Paterson; L J Reed; D G Smith; J Suckling; R Tait; E M Taylor; B J Sahakian; T W Robbins; K D Ersche
Journal:  Transl Psychiatry       Date:  2017-03-07       Impact factor: 6.222

8.  Disturbances across whole brain networks during reward anticipation in an abstinent addiction population.

Authors:  Liam J Nestor; John Suckling; Karen D Ersche; Anna Murphy; John McGonigle; Csaba Orban; Louise M Paterson; Laurence Reed; Eleanor Taylor; Remy Flechais; Dana Smith; Edward T Bullmore; Rebecca Elliott; Bill Deakin; Ilan Rabiner; Anne-Lingford Hughes; Barbara J Sahakian; Trevor W Robbins; David J Nutt
Journal:  Neuroimage Clin       Date:  2020-05-26       Impact factor: 4.881

9.  Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals.

Authors:  Liam J Nestor; Louise M Paterson; Anna Murphy; John McGonigle; Csaba Orban; Laurence Reed; Eleanor Taylor; Remy Flechais; Dana Smith; Edward T Bullmore; Karen D Ersche; John Suckling; Rebecca Elliott; Bill Deakin; Ilan Rabiner; Anne Lingford Hughes; Barbara J Sahakian; Trevor W Robbins; David J Nutt
Journal:  Eur J Neurosci       Date:  2018-11-26       Impact factor: 3.386

10.  Opioid antagonism modulates wanting-related frontostriatal connectivity.

Authors:  Alexander Soutschek; Susanna C Weber; Thorsten Kahnt; Boris B Quednow; Philippe N Tobler
Journal:  Elife       Date:  2021-11-11       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.